고양이 백신 시장(2025-2034년) : 기회, 성장 촉진요인, 산업 동향 분석, 예측

The Global Cat Vaccines Market, valued at USD 1.1 billion in 2024, is anticipated to grow at a CAGR of 9.2% from 2025 to 2034. The primary drivers of this market expansion include the rising awareness of animal health and an increasing number of pet owners worldwide. Vaccination is critical in safeguarding cats from infectious diseases, including feline leukemia, respiratory conditions, and rabies, which are common among both domestic and stray cats. As more people understand the importance of preventative healthcare for their pets, the demand for cat vaccines continues to rise.

Additionally, the growing concern over zoonotic diseases, which can be transmitted from animals to humans, has increased the emphasis on vaccinations, particularly to prevent diseases like rabies. This growing awareness has led to an increased uptake of vaccines, with more pet owners investing in preventive measures for their cats' health. Furthermore, the expanding use of pet insurance and the surge in pet care products and services also contribute to the market growth.

Cat vaccines are designed to protect companion animals, especially cats, from a range of infectious diseases. These vaccines work by stimulating the immune system, thereby preventing the spread of illnesses and promoting the overall health of both indoor and outdoor cats.

The market is segmented based on vaccine type into modified/attenuated live, inactivated, and other vaccine types. The modified/attenuated live vaccines hold the largest share, accounting for 50.5% of the market in 2024. Their effectiveness, ability to trigger strong immune responses, and cost-effectiveness make them highly favored by veterinarians and pet owners. These vaccines provide long-lasting protection against diseases like feline leukemia, panleukopenia, and respiratory illnesses, particularly in high-risk environments such as animal shelters.

The cat vaccines market is also divided by disease type into categories like feline leukemia, panleukopenia, respiratory diseases, rabies, and others. Feline respiratory diseases, including Feline Herpesvirus and Calicivirus, represent the largest segment, due to their high contagiousness and significant health risks to cats, particularly in multi-cat environments.

The vaccines are administered either through injectables or intranasal routes. Injectable vaccines dominate the market because of their proven effectiveness, ease of use, and quick immune response. These vaccines, often available in combination formulations, provide protection against multiple diseases in a single dose, making them convenient and appealing to pet owners.

The combined vaccines segment leads the market, offering protection against several diseases in one shot. These vaccines reduce the number of vet visits and injections, making them more affordable and less stressful for cats.

The market is also segmented by the duration of immunity, with vaccines offering 1-year, 3-year, or other durations. The 1-year immunity vaccines are the most popular, known for their long-standing safety record and efficacy, which solidifies their dominant position in the market.

In North America, the U.S. holds a significant market share, driven by its large pet-owning population and strong veterinary infrastructure, which enhances access to vaccines and veterinary care, further promoting market growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing pet ownership and spending on pet health
    • 3.2.1.2 Growing awareness of preventive pet healthcare
    • 3.2.1.3 Advancements in vaccine technology
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development cost of vaccines
    • 3.2.2.2 Stringent regulatory requirement
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Modified/attenuated live
• 5.3 Inactivated
• 5.4 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Feline respiratory diseases
• 6.3 Feline leukemia
• 6.4 Feline panleukopenia (feline distemper)
• 6.5 Feline rabies
• 6.6 Other disease types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Injectables
• 7.3 Intranasal

Chapter 8 Market Estimates and Forecast, By Component, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Combined vaccine
• 8.3 Mono vaccine

Chapter 9 Market Estimates and Forecast, By Duration of Immunity, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 1 year
• 9.3 3 years
• 9.4 Other durations of immunity

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Bioveta
• 11.2 Boehringer Ingelheim
• 11.3 Durvet
• 11.4 Elanco
• 11.5 Indian Immunologicals
• 11.6 INTAS Animal Health
• 11.7 Merck
• 11.8 Spectra
• 11.9 Virbac
• 11.10 Zoetis